Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
+$1.21 today
- Market cap
- $9.64B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
Volume 1.37M
Average 1.17M
SYRE Operating Cash Flow
Cash generated by the company's core business operations during the period.
Spyre Therapeutics, Inc.NASDAQ: SYRE
Operating Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Operating cash flow growth accelerates
Q3 FY2026 operating cash flow of $77.5M (cash outflow) rose 108.8% year over year, ahead of the +54.0% change in trailing-twelve-month operating cash flow. Sequentially, it rose 10.9% from the prior quarter. Over 3 fiscal years it compounded at +28.3% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +108.8% holds above the trailing-twelve-month pace of +54.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (169.25M) USD
- Year-over-year change
- -7.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (169.25M) | -7.5% |
| FY2024 | 2024-12-31 | (157.41M) | -57.6% |
| FY2023 | 2023-12-31 | (99.91M) | -24.7% |
| FY2022 | 2022-12-31 | (80.14M) | -49.2% |
| FY2021 | 2021-12-31 | (53.72M) | — |
Operating Cash Flow vs competitors
How SYRE compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +54.0% is the 4th highest of 8, against a peer median of +1.1%.
- Operating cash flow amounts to 275.5% of revenue for SYRE, versus a peer median of 623.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $249.32M USD | +54.0% | +28.3% | 275.5% | |
| FY2025 | €155.69M EUR | +1.1% | +42.4% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $139.96M USD | +69.1% | +91.4% | 4213.2% |
| LTM Mar 2026 | $81.33M USD | -1.5% | +9.6% | — | |
| LTM Mar 2026 | $52.21M USD | +323.8% | -11.3% | 623.9% | |
| LTM Mar 2026 | $36.26M USD | -23.7% | -15.4% | 8.5% | |
| LTM Mar 2026 | €28.81M EUR | -39.6% | +0.2% | 98232.5% | |
| LTM Mar 2026 | $4.48M USD | +104.1% | — | 1.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding SYRE) | — | +1.1% | +4.9% | 623.9% | |
Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (65.8M) | (83.82M) | (338.79M) | (208.02M) | (155.2M) |
| Depreciation & Amortization | 1.58M | 1.96M | 744K | 0 | 10M |
| Deferred Income Tax | 0 | (327K) | 0 | 0 | 0 |
| Stock-Based Compensation | 8.04M | 7.11M | 25.68M | 44.83M | 37.61M |
| Change in Working Capital | 1.83M | (5.5M) | (5.21M) | (4.53M) | (5.93M) |
| Accounts Receivables | (815K) | 440K | 375K | 0 | 0 |
| Inventory | 0 | (440K) | 0 | 0 | 0 |
| Accounts Payables | 1.07M | (2.64M) | 218K | (230K) | 7.65M |
| Other Working Capital | 1.58M | (2.86M) | (5.8M) | (4.3M) | (13.58M) |
| Other Non-Cash Items | 638K | 426K | 217.67M | 10.31M | (55.73M) |
| Operating Cash Flow | (53.72M) | (80.14M) | (99.91M) | (157.41M) | (169.25M) |
| Capital Expenditures | (573K) | (38K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 3.04M | 0 | 0 |
| Purchases of Investments | (133.08M) | (39.5M) | (166.8M) | (599.25M) | (522.21M) |
| Sales of Investments | 111.03M | 96.55M | 39.9M | 245.97M | 371.74M |
| Other Investing Activities | 0 | 0 | 15.48M | 0 | 7M |
| Investing Cash Flow | (22.62M) | 57.01M | (108.39M) | (353.29M) | (143.48M) |
| Debt Repayment | (510K) | (418K) | (16K) | 0 | 0 |
| Common Stock Issued | 0 | 42.87M | 169.11M | 236.38M | 314.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.9M | 222K | (5.38M) | 5.67M | (5.41M) |
| Financing Cash Flow | 1.39M | 42.68M | 361.08M | 410.91M | 309.03M |
| Effect of Forex Changes | (15K) | (106K) | 25K | (3K) | 0 |
| Net Change in Cash | (74.96M) | 19.44M | 152.8M | (99.79M) | (3.7M) |
| Free Cash Flow | (54.29M) | (80.18M) | (99.91M) | (157.41M) | (169.25M) |
Spyre Therapeutics, Inc.
NASDAQ:SYRE
Intrinsic Alpha fair value
Locked
Current Price
$101.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.